Aprea Therapeutics, Inc. (APRE): who owns it and who trades it
As of Nov 12, 2026, APRE insiders reported 4 purchases worth $61K in the last 12 months. The largest buyer was Marc Duey (Director), with $25.1K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Aprea Therapeutics
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, APRE insiders reported $61K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Oren Gilad | CEO | Purchase | 28,100 | $0.89 | $25K | Form 4 |
| Jan 30, 2026 | John P. Hamill | CFO | Purchase | 5,700 | $0.89 | $5.1K | Form 4 |
| Dec 10, 2025 | Marc Duey | Director | Purchase | 21,459 | $1.17 | $25.1K | Form 4 |
| Dec 10, 2025 | John P. Hamill | CFO | Purchase | 5,000 | $1.17 | $5.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Marc Duey | Director | $25.1K | – | Dec 10, 2025 |
| Oren Gilad | President/CEO, Director | $25K | – | Jan 30, 2026 |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | $10.9K | – | Jan 30, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
APRE short interest
Low short interest. 4.2% of APRE shares are sold short: about 1 share in 24. Over the last 12 reports the number of shares short went up 256%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 525,159 APRE shares were sold short, 4.2% of the shares outstanding, down 15.5% from the report before. At the average daily volume of 202,413 shares, buying them all back would take about 2.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 525,159 | 4.17% | -15% | 202,413 | 2.6 |
| Oct 15, 2026 | 621,151 | 4.93% | +22% | 278,538 | 2.2 |
| Sep 30, 2026 | 508,841 | 4.04% | -11% | 207,556 | 2.5 |
| Sep 15, 2026 | 574,605 | 4.56% | -7% | 177,428 | 3.2 |
| Aug 31, 2026 | 616,887 | 4.90% | +11143% | 893,115 | 1.0 |
| Aug 14, 2026 | 5,487 | 0.04% | -87% | 46,742 | 1.0 |
| Jul 31, 2026 | 41,083 | 0.36% | -32% | 47,642 | 1.0 |
| Jul 15, 2026 | 60,595 | 0.53% | -22% | 74,736 | 1.0 |
| Jun 30, 2026 | 77,797 | 0.68% | +22% | 100,138 | 1.0 |
| Jun 15, 2026 | 63,530 | 0.55% | -47% | 126,040 | 1.0 |
| May 29, 2026 | 119,012 | 1.04% | -19% | 148,030 | 1.0 |
| May 15, 2026 | 147,564 | 1.29% | +43% | 224,819 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Aprea Therapeutics company events
Aprea Therapeutics filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (listing). The latest was on Nov 4, 2026.
- Nov 4, 2026AnnouncementThe Company updated its corporate presentation slide deck. Filing
- Aug 28, 2026AnnouncementAprea Therapeutics, Inc. issued a press release announcing the expansion of the intellectual property portfolio for its precision oncology programs. Filing
- Aug 12, 2026AnnouncementThe Company updated its corporate presentation slide deck. Filing
- Jul 23, 2026ListingAprea Therapeutics, Inc. received a notification letter from The Nasdaq Stock Market LLC informing the Company that, while the Company has not yet regained compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)… Filing
- Jun 17, 2026VoteReported shareholder vote results. Filing
- May 13, 2026AnnouncementThe Company updated its corporate presentation slide deck. Filing
- Apr 1, 2026AnnouncementShared information with investors. Filing
- Mar 30, 2026AgreementAprea Therapeutics, Inc. entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) pre-funded Common Stock purchase warrants to purchase up to… Filing
- Mar 16, 2026AnnouncementThe Company updated its corporate presentation slide deck. Filing
- Feb 18, 2026AnnouncementAprea Therapeutics, Inc. issued a press release announcing the second unconfirmed partial response (uPR) observed in a patient enrolled in its ongoing Phase 1 ACESOT-1051 dose-escalation study (A Multi-Center Evaluation of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors). Filing
- Jan 29, 2026AgreementAprea Therapeutics, Inc. entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 6,288,857 shares of the Company’s Common Stock, par value… Filing
- Jan 23, 2026ListingAprea Therapeutics, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per… Filing
- Jan 9, 2026AnnouncementAprea Therapeutics, Inc. updated its corporate presentation slide deck. Filing
- Dec 9, 2025AgreementAprea Therapeutics, Inc. entered into a securities purchase agreement with certain accredited investors and Company insiders, pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 2,623,023 shares of the Company’s Common… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Aprea Therapeutics financials
Famous investors that hold APRE
1 of the 50 well-known investors we track reported holding APRE in their latest 13F filing. The largest position is Jim Simons's, worth $74.7K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 99,600 | $74.7K | 0.0% | -6% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Aprea Therapeutics, Inc. (APRE) stock
Are APRE insiders buying or selling?
In the last 12 months, APRE insiders reported 4 open-market purchases worth $61K and no sales. The latest trade was on Jan 30, 2026. See every trade.
What is the short interest in APRE?
As of Oct 30, 2026, 525,159 APRE shares were sold short, 4.2% of the shares outstanding, down 15.5% from the report before. At the average daily volume of 202,413 shares, buying them all back would take about 2.6 trading days (days to cover). See the history.
Which famous investors hold APRE?
1 of the 50 well-known investors we track reported APRE in their latest 13F filing, including Jim Simons. The largest position is worth $74.7K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.